PRODUCT INFORMATION



Fumagillol

Item No. 39766

CAS Registry No.: Formal Name:	(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-	
	2-methyl-3-(3-methyl-2-buten-1-yl)-2- oxiranyl]-1-oxaspiro[2.5]octan-6-ol	O _H
Synonyms:	(–)-Fumagillol	
MF:	$C_{16}H_{26}O_4$	
FW:	282.4	
Purity:	≥95%	
Supplied as:	A solid	ÓН I
Storage:	-20°C	
Stability:	≥4 years	
Item Origin:	Synthetic	
Information represents the product expectitications. Patch expectitic analytical results are provided on each cortificate of analytic		

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Fumagillol is supplied as a solid. A stock solution may be made by dissolving the fumagillol in the solvent of choice, which should be purged with an inert gas. Fumagillol is soluble in chloroform, ethanol and methanol.

Description

Fumagillol is a sesquiterpenoid that has been found in P. jensenii and has diverse biological activities.¹⁻⁴ It is an inhibitor of methionyl aminopeptidase 2 (METAP2; $IC_{50} = 230 \text{ nM}$ for the human enzyme).¹ Fumagillol is active against the parasite *G. lamblia* ($IC_{50} = 3.4 \mu M$).² It reduces the proliferation of isolated calf pulmonary artery endothelial cells ($IC_{50} = 8.09 \mu M$) and human umbilical vein endothelial cells (HUVECs; $EC_{50} = 1000 \mu M$) and human umbilical vein endothelial cells (IUVECs; $EC_{50} = 1000 \mu M$) and human umbilical vein endothelial cells (IUVECs; $EC_{50} = 1000 \mu M$) and human umbilical vein endothelial cells (IUVECs; $EC_{50} = 1000 \mu M$) and human umbilical vein endothelial cells (IUVECs; $EC_{50} = 1000 \mu M$) and human umbilical vein endothelial cells (IUVECs; $EC_{50} = 1000 \mu M$) and human umbilical vein endothelial cells (IUVECs; $EC_{50} = 1000 \mu M$) and human umbilical vein endothelial cells (IUVECs; $EC_{50} = 1000 \mu M$) and human umbilical vein endothelial cells (IUVECs; $EC_{50} = 1000 \mu M$) and human umbilical vein endothelial cells (IUVECs; $EC_{50} = 10000 \mu M$) and human umbilical vein endothelial cells (IUVECs; $EC_{50} = 1000 \mu M$) and human umbilical vein endothelial cells (IUVECs; $EC_{50} = 10000 \mu M$) and human umbilical vein endothelial cells (IUVECs; $EC_{50} = 10000 \mu M$) and human umbilical vein endothelial cells (IUVECs; $EC_{50} = 10000 \mu M$) and human umbilical vein endothelial cells (IUVECs; $EC_{50} = 10000 \mu M$) and human umbilical vein endothelial cells (IUVECs; $EC_{50} = 10000 \mu M$) and human umbilical vein endothelial cells (IUVECs; $EC_{50} = 10000 \mu M$) and human umbilical vein endothelial cells (IUVECs; $EC_{50} = 10000 \mu M$) and human umbilical vein endothelial cells (IUVECs; $EC_{50} = 10000 \mu M$) and human umbilical vein endothelial cells (IUVECs; $EC_{50} = 10000 \mu M$) and human umbilical vein endothelial cells (IUVECs; $EC_{50} = 10000 \mu M$) and human umbilical vein endothelial cells (IUVECs; $EC_{50} = 10000 \mu M$) and human umbilical vein endothelial cells (IUVECs; $EC_{50} = 10000 \mu M$) 49 nM).^{1,3} Fumagillol inhibits the proliferation of isolated mouse splenocytes in a mixed lymphocyte reaction (IC₅₀ = 250 nM).⁴

References

- 1. Fardis, M., Pyun, H.-J., Tario, J., et al. Design, synthesis and evaluation of a series of novel fumagillin analogues. Bioorg. Med. Chem. 11(23), 5051-5058 (2003).
- 2. Padia, J., Kulakova, L., Galkin, A., et al. Discovery and preclinical development of antigiardiasis fumagillol derivatives. Antimicrob. Agents Chemother. 64(10), e00582-20 (2020).
- Kim, D., Min, J., Ahn, S.K., et al. 5-Demethoxyfumagillol, a potent angiogenesis inhibitor isolated from 3. Aspergillus fumigatus. Chem. Pharm. Bull. (Tokyo) 52(4), 447-450 (2004).
- Hatanaka, H., Hashimoto, M., Tsurimi, Y., et al. FR65814, a novel immunosuppressant isolated from a 4. Penicillium strain. Taxonomy, fermentation, isolation, physico-chemical and biological characteristics and structure assignment. J. Antibiot. (Tokyo) 41(8), 999-1008 (1988).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 10/10/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM